论文信息 - Rethinking clinical delivery of adult stem cell therapies - 字舞流文

Rethinking clinical delivery of adult stem cell therapies

A transformation needs to take place in the way we manufacture and deliver adult stem cell therapies.

Nuala Trainor | A. Pietak | Alexis Pietak | Tim Smith | T. Smith | N. Trainor

[1] Ivan Martin,et al. Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products. , 2009, Trends in biotechnology.

[2] Dieter Wirz,et al. Bioreactor based engineering of large-scale human cartilage grafts for joint resurfacing. , 2010, Biomaterials.

[3] D. Porter. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. , 2011, Hematology. American Society of Hematology. Education Program.

[4] M. Kassem,et al. Human mesenchymal stem cells: from basic biology to clinical applications , 2008, Gene Therapy.

[5] Michael Freeman,et al. Does the FDA have regulatory authority over adult autologous stem cell therapies? 21 CFR 1271 and the emperor's new clothes , 2012, Journal of Translational Medicine.

[6] D. G. Halme,et al. FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[7] R. Weisel,et al. Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair , 2010, Circulation.

[8] Richard J. Lilford,et al. Investing in new medical technologies: A decision framework , 2007 .

[9] R. Atoui,et al. Concise Review: Immunomodulatory Properties of Mesenchymal Stem Cells in Cellular Transplantation: Update, Controversies, and Unknowns , 2012, Stem cells translational medicine.

[10] Ownership and Use of Tissue Specimens for Research , 2004 .